Photo credits: sciencemag.org
A study in U.S. nursing homes has shown for the first time that monoclonal antibodies, mass-produced in a laboratory, can protect people from developing symptomatic COVID-19. Their manufacturer, Eli Lilly, hopes these antibodies will provide an additional way to protect people at risk of serious disease from the pandemic coronavirus. But given the success of COVID-19 vaccines and their increasing availability, it’s not clear that the expensive and somewhat cumbersome intervention will be widely used.
Check out the full story right here.